Báo cáo khoa học: Tumour necrosis factor-a attenuates insulin action on phosphoenolpyruvate carboxykinase gene expression and gluconeogenesis by altering the cellular localization of Foxa2 in HepG2 cells pptx

Tumour necrosis factor-a attenuates insulin action on phosphoenolpyruvate carboxykinase gene expression and gluconeogenesis by altering the cellular localization of Foxa2 in HepG2 cells Amit K. Pandey, Vikash Bhardwaj* and Malabika Datta Institute of Genomics and Integrative Biology (CSIR), Delhi, India Introduction Type 2 diabetes, which accounts for almost 90% of the total diabetic population, stems from the decreased responsiveness of the body to insulin (insulin resis- tance), accompanied by the failure of pancreatic b-cells to secrete insulin to counteract this insulin-resistant state. Obesity is invariably associated with diabetes Keywords diabetes; Foxa2; insulin; phosphoenolpyruvate carboxykinase (PEPCK); tumour necrosis factor-a (TNFa) Correspondence M. Datta, Institute of Genomics and Integrative Biology, Mall Road, Delhi-110 007, India Fax: +91 11 27667471 Tel: +91 11 27667439, 27667602, ext. 135 E-mail: mdatta@igib.res.in *Present address Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India (Received 19 January 2009, revised 18 March 2009, accepted 12 May 2009) doi:10.1111/j.1742-4658.2009.07091.x Circulating tumour necrosis factor-a (TNFa) levels, which are elevated in obesity-associated insulin resistance and diabetes, inhibit insulin signalling at several points in the signalling cascade. The liver is critical in maintaining cir- culating glucose levels and, in a preliminary investigation using the human hepatoma (HepG2) cell line in this study, we demonstrated the role of TNFa in the regulation of this phenomenon and determined the underlying molecular mechanisms. As the transcription factor Foxa2 has been impli- cated, in part, in the regulation of gluconeogenic genes, we studied the effects of TNFa and ⁄ or insulin on its cellular status in hepatocytes, followed by an assessment of its occupancy on the phosphoenolpyruvate carboxykinase (PEPCK) promoter. Preincubation of cells with TNFa, followed by insulin, significantly prevented insulin-mediated nuclear exclusion of Foxa2 and sub- stantially increased its nuclear concentration. Foxa2 was subsequently found to occupy its binding element on the PEPCK promoter. TNFa alone, how- ever, did not alter the status of cellular Foxa2 or its occupancy on the PEP- CK promoter. TNFa preincubation also significantly attenuated insulin- induced inhibition of the expression of gluconeogenic enzymes and hepatic glucose production. Insulin inhibition of PEPCK expression and the preven- tive effect of TNFa could be partially but significantly restored in the pres- ence of Foxa2 siRNA. Several other well-known mediators of insulin action in the liver in general and of gluconeogenic genes in particular include Foxo1, PGC-1 and SREBP-1c. Our results indicate that another transcription factor, Foxa2, is at least partly responsible for the attenuating effect of TNFa on insulin action on PEPCK expression and glucose production in HepG2 cells. Structured digital abstract l MINT-7040448: TBP (uniprotkb:P20226), FOXA2 (uniprotkb:Q9Y261) and FOXA1 (uni- protkb: P55317) colocalize (MI:0403)bycosedimentation (MI:0027) Abbreviations F1,6bpase, fructose-1,6-bisphosphatase; G6Pase, glucose-6-phosphatase; Hnf-3, hepatocyte nuclear factor 3; PEPCK, phosphoenolpyruvate carboxykinase; TBP, TATA box-binding protein; TNFa, tumour necrosis factor-a. FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS 3757 and a parallel increase in the occurrence of both is evident across all populations [1,2]. Obesity-induced insulin resistance is thereby characterized by a loss of insulin sensitivity mediated by factors released from adipocytes, mainly free fatty acids and proteins, termed adipocytokines, which act to control various metabolic functions [3–6] with well-described physio- logical effects [7]. One such adipocytokine is tumour necrosis factor-a (TNFa), which has been identified as a significant contributor to insulin resistance, and its levels have been reported to be increased significantly in obese diabetic individuals and in several animal models of obesity [8–12]. The liver is a major insulin target tissue and plays a significant role in glucose homeostasis, as it can alternate between cycles of glucose output and its inhibition to maintain normal circulating glucose levels [13]; it is this precisely regulated cycle that is disturbed under conditions of insulin resistance and type 2 diabe- tes. Nuclear transcription factors that are crucial in governing this metabolic switch are regulated by circulating levels of insulin and glucagon [14]. Insulin triggers the activation of a series of phosphorylation cascades that are lost in insulin-resistant states, thereby preventing insulin from correctly regulating glucose and fat metabolism [15]. The hepatocyte nuclear factor 3 (Hnf-3) forkhead family of nuclear transcription factors, which includes three members designated as Foxa-1 (Hnf-3a), Foxa-2 (Hnf-3b) and Foxa-3 (Hnf-3c) [16–18], play an impor- tant regulatory role in the maintenance of normal glu- cose homeostasis; they do so by regulating the gene expression of rate-limiting enzymes of gluconeogenesis and glycogenolysis, including phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), and by regulating glucagon and Pdx-1 gene expression in the pancreas [17,19–22]. In addition, although some reports have shown the regulation of gluconeogenic enzymes by another forkhead transcrip- tion factor, Foxo1 [23,24], others have reported that the overexpression of Foxo1 carries the message to G6Pase only and that PEPCK levels remain unaffected [25,26]. Thus, the mechanisms involved in the regula- tion of gluconeogenic enzymes are very controversial, and it is thereby hypothesized that both of these fac- tors contribute to insulin action on glucose production by regulating the expression of different gluconeogenic enzymes [17], and ⁄ or synchronize with other transcrip- tion factors to regulate the same. In view of these controversial reports, we sought to decipher the role of Foxa2 (HNF-3b), if any, in the regulation of gluconeogenesis in HepG2 cells, and the effects of TNFa pretreatment on this phenomenon, with an objective to decode its regulation in obesity and insulin resistance. Although HepG2 cells are hepa- toma cells, they retain several normal human liver properties, including the synthesis of albumin, lipopro- tein and several other liver-specific functions, and, most importantly, these functions are stable through passages. They are therefore valuable in the study of several hepatic functions and other aspects of metabo- lism, and have been recognized as an in vitro human model system [27,28]. In this article, we report that Foxa2, in part, is critical in the attenuating effects of TNFa on insulin-mediated Foxa2 localization in HepG2 cells, and the ensuing effect on gluconeogenesis and glucose output. Our results show that, in the pres- ence of TNFa, insulin-induced inhibition of gluconeo- genesis and glucose output is attenuated and Foxa2, at least in part, plays an important role in this effect. The results presented here require subsequent validation in primary cells and animal models but, as a preliminary step, they unravel one of the mechanisms of TNFa- mediated withdrawal of insulin action in HepG2 cells. Results Incubation of HepG2 cells with TNFa attenuates insulin-stimulated Akt phosphorylation and nuclear exclusion of Foxa2 in HepG2 cells Initially, we determined whether the cells were insulin unresponsive in our study at the dose and period of TNFa preincubation prior to insulin treatment used. Akt is one of the most important insulin signalling intermediates, and is well known to be activated by insulin, an effect that is equally well known to be pre- vented in cells preincubated with TNFa prior to insu- lin incubation. Gupta et al. [29] and Gupta and Khandelwal [30] have demonstrated previously that insulin-stimulated Akt phosphorylation is significantly prevented in HepG2 cells preincubated with TNFa prior to insulin incubation. Interestingly, HepG2 cells overexpressing a constitutively active form of Akt demonstrated restoration of this preventative effect of TNFa on insulin action [30]. As our study was direc- ted towards the underlying mechanisms of insulin and TNFa pretreatment on gluconeogenesis within the hepatocyte, we started by studying the status of Akt under the aforesaid conditions. Insulin significantly stimulated Akt phosphorylation relative to the control (P < 0.001), and this effect was decreased significantly on TNFa pretreatment (P < 0.01) (Fig. 1A,B). The inhibition of insulin signalling in the liver is pri- marily reflected by the attenuation of the insulin-medi- ated inhibition of gluconeogenic gene expression. As Effect of TNFa on insulin action on PEPCK expression A. K. Pandey et al. 3758 FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS the forkhead protein, Foxa2, has been suggested to regulate, at least in part, the expression of gluconeo- genic genes [17,31], we studied its status within the cell in the given experimental conditions. Foxo1, another member of the forkhead family of transcription factors, is a very well-established mediator of the effects of insulin on gluconeogenic gene expression [24], and has also been implicated in several cellular effects of TNFa [32,33]. Together with Foxa2, we also assessed its cellular status in the presence and absence of insulin and ⁄ or TNFa. Figure 2A, B shows the effects of TNFa pretreatment on insulin action on the localization of Foxa2 and Foxo1 within the cell. Incu- bation with 50 nm insulin resulted in relative nuclear exclusion of Foxa2, with significant localization in the cytosol (P < 0.01 relative to control). An identical but more pronounced trend was observed for Foxo1, implying that it is a much stronger candidate for insu- lin action. Surprisingly, in cells pretreated with TNFa (1 nm, 24 h), followed by insulin incubation, Foxa2 was found to be mainly localized in the nucleus (P < 0.05) and was significantly ( P < 0.01) less detected in the cytosol, relative to cells incubated in the presence of insulin alone. Foxo1 also showed an almost complete nuclear localization in cells pretreated with TNFa prior to insulin incubation, whereas, in cells incubated in the presence of insulin alone, it was exclusively localized in the cytosol. As Foxo1 is already known to mediate the effects of insulin on glu- coneogenic genes, we carried out further experiments to decipher the role of Foxa2 only, if any, on these series of events. There was no significant alteration in Foxa2 localization in cells treated with TNFa alone relative to cells incubated in the absence of any of these reagents (Control) (Fig. 2A–C). These results imply that, in the presence of TNFa, wherein cells are rendered insulin insensitive, insulin-mediated nuclear exclusion and inactivation of Foxa2 are prevented, with the result that it is primarily localized in the nucleus. Thus, although TNFa alone does not alter the status of Foxa2 within the cell, it attenuates insu- lin-stimulated Foxa2 nuclear exclusion, possibly by blunting insulin signalling within the cell. The subcellu- lar distribution of Foxa2 under the conditions stated above was also checked by immunofluoresence staining with anti-Foxa2 IgG. In cells incubated with 50 nm insulin, Foxa2 was fairly strongly detected in the cyto- sol, when compared with cells incubated in the absence of insulin. Although Foxa2 was not completely excluded from the nucleus by treatment with insulin, it was strongly detected in the cytosol of insulin-treated cells, but was largely absent in control cells. However, when cells were pretreated with TNFa (1 nm,24h) prior to insulin incubation, this nuclear extrusion of Foxa2 and its localization in the cytosol were signifi- cantly attenuated, with the result that, in these TNFa- pretreated cells, Foxa2 was very weakly detected in the cytosol with the major fraction being in the nucleus (Fig. 2C). TNFa pretreatment increases Foxa2 occupancy on the PEPCK promoter As we observed a predominant localization of Foxa2 in the nuclei of cells pretreated with TNFa prior to insulin incubation, and considering its possible involve- ment in the regulation of gluconeogenic enzymes, we analysed the Foxa2 occupancy of the promoter of gluconeogenic genes, mainly PEPCK, it being the rate-limiting enzyme, to categorically determine whether Foxa2 can exert its effects on the transcrip- tional regulation of its targets in the absence and presence of TNFa and ⁄ or insulin. Foxa2 occupancy of p-AKT AKT TNFα α (1 nM) +– –– –+ ++Ins (50 n M) Con TNF α TNF α + Ins Ins 400 350 300 250 200 150 100 50 * p-Akt Arbitrary units ** 0 A B Fig. 1. Effect of TNFa on insulin-stimulated Akt activation in HepG2 cells. Serum-starved HepG2 cells were incubated in the absence or presence of TNFa (1 n M, 24 h) and then with or without insulin (50 n M, 15 min). Cellular lysate (50 lg) from each group was resolved by SDS-PAGE, transferred to poly(vinylidene difluoride) membranes and probed by western blotting with p-Akt and Akt (total) antibodies. Each band is a representative of three indepen- dent blots (A). Signals were scanned, analysed densitometrically and intensities are expressed as arbitrary units (B). Values are the means ± SEM of three experiments. *P < 0.001 when compared with control; **P < 0.01 when compared with incubation with insulin alone. A. K. Pandey et al. Effect of TNFa on insulin action on PEPCK expression FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS 3759 the PEPCK promoter was determined by semiquantita- tive (Fig. 3A,B) and quantitative (Fig. 3C) RT-PCR. When compared with the control, insulin caused a significant marginal (P < 0.01) decrease in Foxa2 occupancy of the PEPCK promoter. This decrease was significantly (P < 0.01) attenuated in cells preincubat- ed in the presence of TNFa prior to insulin incubation. In cells incubated in the presence of TNFa alone, Foxa2 did not show any significant change in its occu- pancy on the PEPCK promoter after normalization with the input DNA and comparison with the control. All of these results indicate that preincubation with TNFa significantly abrogates the insulin-mediated decrease in Foxa2 occupancy of the PEPCK promoter, with the result being that, under these conditions, Foxa2 significantly occupies its binding element on the PEPCK promoter which, however, is not observed in cells incubated in the presence of TNFa alone. Effect of TNFa pretreatment on PEPCK and G6Pase mRNA in HepG2 cells Gluconeogenesis is a very significant phenomenon in the liver, and gluconeogenic enzymes, namely PEPCK, Foxa2 Foxa2 Foxo1 Foxo1 TBP β -actin TBP β -actin Nuclear pellet Cytosol Con TNFα + Ins TNFα Ins Con TNFα + Ins TNFα Ins A C 120 60 80 100 Foxo1 Foxa2 Nuclear pellet ** b 0 20 40 * a Con TNFα + Ins TNFα Ins 160 200 240 Foxa2 Foxo1 * a Relative arbitrary units Cytosol 40 80 120 *** c 0 B DAPI FITC Merge Control TNF α + Insulin Insulin TNF α Fig. 2. Effect of TNFa on Foxa2 and Foxo1 localization. HepG2 cells were incubated with TNFa (1 nM) or insulin (50 nM), or pretreated with TNFa (1 n M, 24 h) followed by insulin treatment (50 nM, 15 min). Cells incubated in the absence of any of these were taken as the control (Con). On termination of incubation, cells were lysed and the nuclear (50 lg) and cytosolic (40 lg) protein extracts were assessed for the presence of Foxa2 or Foxo1 by western blotting. Each band is a representative of three separate blots from three independent experiments. Blots were probed with TBP and b-actin antibodies and taken as nuclear and cytosolic loading controls, respectively, and also used to ascer- tain the purity of the nuclear and cytosolic preparations (A). Bands were scanned, quantified densitometrically and are expressed as arbitrary units (a.u). Values depicted are the means ± SEM of three values obtained from three independent blots (B). (C) HepG2 cells were incu- bated as described in (A) and Foxa2 localization was detected by incubation with anti-Foxa2 IgG and fluorescein isothiocyanate-linked sec- ondary antibody. Cells were visualized in a fluorescence microscope at a magnification of ·40. DAPI, 4¢,6-diamidino-2-phenylindole; FITC, fluorescein isothiocyanate. *P < 0.01 when compared with control; **P < 0.05 when compared with insulin incubation (nuclear pellet); ***P < 0.01 when compared with insulin incubation (cytosol). a P < 0.001 when compared with control; b P < 0.01 and c P < 0.001 when compared with incubation with insulin alone. Effect of TNFa on insulin action on PEPCK expression A. K. Pandey et al. 3760 FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS fructose-1,6-bisphosphatase (F1,6bpase) and G6Pase, are critical in determining the rate of gluconeogenesis and hepatic glucose production. Considering these phenomena, which are elevated under diabetic condi- tions, and also the fact that, in cells that are rendered insulin insensitive by TNFa, there is a relatively increased nuclear translocation of Foxa2, we studied the resulting effects of TNFa pretreatment on the effect of insulin on the expression of PEPCK and another glu- coneogenic enzyme, G6Pase. Compared with the con- trol, insulin incubation caused a significant inhibition of PEPCK and G6Pase gene expression (P < 0.001, Fig. 4B). However, TNFa pretreatment prior to insulin incubation considerably attenuated this inhibitory effect (PEPCK, P < 0.01; G6Pase, P < 0.05; when compared with insulin alone). This indicates that, in the presence of TNFa, HepG2 cells do not respond to insulin and the subsequent enhanced occupation of Foxa2 on its bind- ing element (as observed in the case of PEPCK) leads to elevated levels of these gene transcripts. When compared with the control, TNFa alone caused a significant (P < 0.05) inhibition of PEPCK and G6Pase tran- scripts. However, as described in the earlier results, Foxa2 localization and occupancy on the PEPCK pro- moter in cells incubated in the presence of TNFa alone were not altered significantly from those of the control; these results indicate that, although PEPCK and G6Pase transcripts are decreased in cells incubated in the presence of TNFa and insulin alone, the upstream events facilitating this are possibly different, with Foxa2, at least in part, mediating the insulin effect. Real-time PCR data also depicted an identical pattern, in which PEPCK and G6Pase mRNA were significantly (P < 0.001) inhibited in the presence of insulin; how- ever, this was not observed when the cells were pretreat- ed with TNFa prior to insulin treatment (P < 0.001; Fig. 4C). TNFa also inhibited significantly the levels of PEPCK and G6Pase gene transcripts (P < 0.01). The specificity of Foxa2 was checked with the use of Foxa2 siRNA that could knock down Foxa2 protein levels by almost 70% (data not shown). Incubation with Foxa2 siRNA prior to insulin treatment could only partially withdraw insulin-mediated inhibition of PEPCK gene expression (P < 0.05, Fig. 4D), and a complete restora- tion was not observed, indicating that Foxa2 is critical, but not the sole mediator, of insulin effects. The preven- tative effect of TNFa on insulin-mediated inhibition of PEPCK expression was also partially reversed by Foxa2 siRNA in cells pretreated with TNFa prior to insulin incubation (P < 0.05). TNFa attenuates insulin-induced inhibition of hepatic glucose output in HepG2 cells As we had observed, so far, an increase in gluconeogenic gene transcript levels in TNFa-pretreated cells as a 2.5 1 1.5 2 * ** 0 0.5 Foxa2 binding normalized to input (arbitary units) Con Ins TNF α + Ins TNF α *** * Foxa2 binding to PEPCK promoter (normalized to input) Con Ins TNF α + Ins TNF α Foxa2 Input IgG Con Ins TNF α + Ins TNF α A B C 2.5 1 1.5 2 0 0.5 Fig. 3. Effect of TNFa on PEPCK promoter occupancy by Foxa2 in HepG2 cells. Cells were pretreated with TNFa (1 n M) followed by insu- lin incubation (50 n M), or incubated with TNFa or insulin alone. On termination of incubation, nuclear chromatin was isolated and immu- noprecipitated with either normal IgG or anti-Foxa2 IgG. The chroma- tin–antibody aggregates were pulled down with protein A-Sepharose and the occupancy of Foxa2 on the PEPCK promoter was determined by semiquantitative (A, B) and real-time quantitative (C) PCR using primers enclosing the Foxa2 binding sites on the PEPCK promoter. The relative quantity of Foxa2 occupancy was determined by the rela- tive standard curve method. Each value presented has been normal- ized with that of input DNA and is the mean ± SEM of three independent values. *P < 0.01 when compared with control; **P < 0.01 and ***P < 0.05 when compared with insulin incubation. A. K. Pandey et al. Effect of TNFa on insulin action on PEPCK expression FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS 3761 result of a decrease in the effects of insulin, mediated in part, by the transcription factor, Foxa2, we sought to determine the effect(s) of this on glucose production from HepG2 cells, the ultimate phenotype that, together with glucose uptake, regulates the circulating glucose level within the body. The incubation of HepG2 cells with insulin inhibited glucose release by almost threefold when compared with the control (P < 0.01); pretreat- ment with TNFa prior to insulin incubation significantly attenuated this inhibition (P < 0.001), i.e. in the pres- ence of TNFa, the extent of inhibition of hepatic glucose output by insulin was markedly attenuated (Fig. 5). Discussion TNFa, which is widely implicated in obesity-associated insulin resistance, impairs the insulin signalling pathway [4–6,29,30,34,35]; however, its role in hepatic gluconeogenesis during insulin resistance and the com- plex underlying mechanisms are not well understood. Impaired glucose tolerance and insulin resistance are early metabolic disturbances in the development of type 2 diabetes. Glucose homeostasis in the body is largely controlled by the liver, and hyperglycemia, as observed in type 2 diabetes, reflects increased hepatic glucose production [36,37], as well as reduced glucose uptake [38]. Indeed, the onset of hepatic insulin resis- tance typically precedes peripheral insulin resistance in humans [39]. The stimulation of gluconeogenesis occurs invariably as a result of increased activity of PEPCK, G6Pase and F1,6bpase, and the targeted overexpression or knockouts of these enzymes play a major regulatory role in glucose homeostasis [40,41]. As far as the regulation of these genes is con- cerned, the Foxa family of transcription factors acts synergistically with other hepatocyte nuclear factors to TNFα α (1 n M ) Ins (50 n M ) +– –– –+ ++ PEPCK 18S G6Pase 0.9 1.2 1.5 PEPCK/18S G6Pase/18S ** *** *** *** ** 0 0.3 0.6 Arbitrary units * Con TNF α TNF α + Ins Ins 0.8 1 1.2 PEPCK/18S G6Pase/18S * * ** ** 0.4 0.6 * * 0 0.2 Con TNF α TNF α + Ins Ins Relative mRNA levels 0.8 1 1.2 Control Insulin TNFα TNFα + Insulin 0.2 0.4 0.6 a b,c 0 Control siRNA Foxa2 siRNA Relative PEPCK mRNA levels normalized to 18S rRNA A B DC Fig. 4. Analysis of PEPCK and G6Pase expression following TNFa treatment. HepG2 cells were pretreated with TNFa (1 nM, 24 h), followed by insulin incubation (50 n M, 4 h), or incubated with TNFa or insulin alone for the respective indicated times. Cells in the absence of any of these were taken as the control (Con). Two micrograms of total RNA were reverse transcribed with random primers and the levels of PEP- CK and G6Pase mRNA were measured by RT-PCR using gene-specific primers. 18S rRNA was taken as the internal loading control (A). Each band was analysed densitometrically and the values are depicted after normalization of PEPCK and G6Pase bands with those of 18S rRNA (B). Each point is the mean ± SEM of three sets of experiments. (C) Real-time PCR quantification of PEPCK and G6Pase mRNA in cells incu- bated as described in (A). Values were normalized to those of 18S rRNA and are the means ± SEM of three independent experiments. (D) Real-time PCR quantification of PEPCK in cells transfected with either control or Foxa2 siRNA prior to incubation as described in (A) above. Values are the means ± SEM of three independent experiments after normalization with 18S rRNA. *P < 0.001 when compared with control (B) and control vs. insulin and TNFa plus insulin vs. insulin alone (C); **P < 0.01 when compared with insulin alone (B) and TNFa incubation when compared with control (C); ***P < 0.05, TNFa plus insulin vs. insulin alone and TNFa alone compared with control (B). a,b P < 0.05 when compared with insulin alone and TNFa plus insulin, respectively, in the presence of control siRNA; c P < 0.05 when compared with insulin alone in the presence of Foxa2 siRNA (D). Effect of TNFa on insulin action on PEPCK expression A. K. Pandey et al. 3762 FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS coordinately regulate liver-specific gene expression [42]. Their transcriptional regulation, particularly that of PEPCK by insulin, is protein synthesis independent, but involves the participation of several transcription factors, including Foxo1, Foxo3, PGC-1a, SREBP etc., although none can be singled out to mediate the effect of insulin. The PEPCK promoter is undoubtedly complex and possesses the binding elements of several transcription factor complexes [43]. The regulation by the Foxa group of transcription factors, which possess considerably identical DNA-binding domains and bind to the promoters of target genes as monomers, is even more controversial. Foxa2 plays a significant regula- tory role in hepatic and ⁄ or pancreatic physiology [16– 22,44–47]. It is excluded from the nucleus as a result of its phosphorylation at Thr156 by Akt, resulting in its inactivation and subsequent repression of the tran- scriptional response of key gluconeogenic enzymes [17]. Zhang et al. [31] have also demonstrated that Foxa2 is required for hepatic gluconeogenesis, the acti- vation of PEPCK is significantly downregulated in the absence of Foxa2, and a clear enrichment of its pro- moter by Foxa2 antibody has been reported [31,48]. Similar results in relation to the identification of a Foxa2-binding site within the PEPCK promoter have also been reported by others [20,22,49,50], and Wolf- rum et al. [17] suggested that Foxa2 may contribute to hepatic insulin resistance in Akt) ⁄ ) mice as a result of an inability to phosphorylate Foxa2 and suppress the transcription of gluconeogenic enzymes. Based on their results, O’Brien et al. [20] reported that insulin mediates its negative effect on glucocorticoid-induced PEPCK gene transcription by inhibiting the binding of Hnf-3 proteins. However, Hall et al. [51] reported that insulin response sequences themselves are not sufficient for the complete effect of insulin on its targets. They found insulin-mediated dissociation of glucocorticoid- induced accumulation of several transcription factors, including Foxa2, from the PEPCK promoter. Taken together, several transcription factors act in tandem to regulate PEPCK gene transcription in response to insulin, and none has been definitively established as physiologically mediating the basal, as well as hor- mone-mediated, alterations in PEPCK gene expression. In this study, we found Foxa2 to be predominantly localized in the nuclei of HepG2 cells incubated with TNFa prior to insulin incubation. As reported earlier, insulin incubation resulted in a relative increase in the nuclear exclusion of Foxa2, with it being strongly localized in the cytosol. TNFa alone, however, did not alter the status of Foxa2 localization when compared with the control. These results imply that, in a TNFa- mediated insulin-resistant cell, insulin-induced nuclear exclusion of Foxa2 is reasonably prevented, with the result that the majority is localized in the nucleus. Pre- treatment with TNF a prior to insulin also led to enhanced binding to the PEPCK promoter by Foxa2. In our study, Foxa2 localization and its subsequent effects therefore appear to be modest, but steady, which points to the fact that other mechanisms and factors are also crucial in mediating the effects of insu- lin [51]. That this is so corroborates well, considering the complexity of the PEPCK promoter, which harbours the binding elements of several transcription factors [43]. Another such transcription factor and a strong regulator of gluconeogenesis is the protein, Foxo1 [24]. This is a very well-studied transcription factor regulating insulin action on gluconeogenic enzymes. Our results also show an increased nuclear extrusion of Foxo1 in the presence of insulin. How- ever, some reports have stated that insulin-mediated phosphorylation inactivates Foxo1, but, surprisingly, the message is carried only onto G6Pase and not to PEPCK, as evident from studies on epithelial kidney cells which lack Foxa2 but express Foxo1 [25]. Along similar lines, Barthel et al. [26] reported that the over- expression of Foxo1 in rat hepatoma cells increased G6Pase transcript levels without affecting those of PEPCK. In the light of this, our results identify Foxa2 as a crucial mediator which, at least in part, plays a significant role in TNFa-mediated abrogation of insu- lin signalling within hepatocytes. 1.4 1 . 6 P < 0.001 0.8 1 1.2 ** Hepatic glucose release (µg·mg –1 protein) 0 0.2 Con TNF α TNF α + Ins Ins 0.4 0.6 * Fig. 5. TNFa attenuates insulin-induced inhibition of hepatic glu- cose output. HepG2 cells were serum starved overnight and incu- bated for 24 h in the presence of TNFa (1 n M) or insulin (50 nM) alone, or pretreated with TNFa followed by insulin for these time periods. Control cells were incubated in the absence of any of these agents. On termination of incubation, the glucose released in the medium was assayed as described in Materials and methods, and the values were normalized to the total cellular protein content. Each value is the mean ± SEM of three independent incubations. *P < 0.01 when compared with control; **P < 0.001 when com- pared with insulin incubation. A. K. Pandey et al. Effect of TNFa on insulin action on PEPCK expression FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS 3763 Consequent to the increased presence of Foxa2 in the nuclei of cells pretreated with TNFa, insulin inhibi- tion of both PEPCK and G6Pase was significantly prevented in such cells. Experiments with Foxa2 siR- NA showed that decreased levels of the Foxa2 protein marginally but significantly restored both insulin inhi- bition of PEPCK expression and the prevention of this by TNFa. This probably contributes towards the observed hyperglycaemic status in obese diabetics. In cells incubated in the presence of TNFa alone, although there was a significant inhibition of gluconeo- genic gene transcription, we did not observe any alter- ation of Foxa2 localization, probably meaning that, although both insulin and TNFa alone decrease the transcription of gluconeogenic genes, Foxa2 may not be involved in the TNFa effect. This could be a possi- bility considering the complex promoter regulation of PEPCK [52,53]. It has been shown recently that the nuclear corepressor is required in the TNFa-mediated inhibition of PEPCK [54]. Therefore, in cells preincu- bated with TNFa prior to insulin, insulin signalling is prevented, resulting in abrogation of this inhibitory effect on PEPCK expression. PEPCK overexpression, in turn, has been shown to attenuate insulin signalling and hepatic insulin sensitivity in transgenic mice [41,55]. Interestingly, adipose selective overexpression of PEPCK led to increased glyceroneogenesis, increased fat mass and adipose size, increased body weight and severe susceptibility to diet-induced insulin resistance [56,57]. Circulating TNFa levels, which are elevated in obese diabetic individuals [8], inhibit several mediators of the insulin signalling cascade [4–6,29,30,34,35], and this leads to the prevention of insulin-mediated inhibition of hepatic glucose output. Indeed, whole-body infusion with TNFa is associated with a significant increase in hepatic glucose output as a result of an impaired abil- ity of insulin to suppress hepatic glucose production [58,59]. In this article, we have demonstrated that TNFa pretreatment prevents insulin-induced inhibition of hepatic glucose output, indicating that, in such con- ditions, cells become insulin insensitive; this is in agree- ment with studies in which the overexpression of IKKb, a downstream mediator of TNFa signalling, leads to local and systemic insulin resistance, whereas mice lacking this enzyme in the liver retain liver insulin responsiveness [60,61]. In summary, our results have unfolded a series of events beginning with the TNFa-mediated prevention of the effect of insulin on Foxa2 localization and lead- ing to the abrogation of insulin inhibition of gluconeo- genesis and glucose output in HepG2 cells. Although TNFa-mediated inhibition of insulin signalling has been known for some time, the focus has primarily been on glucose uptake in the skeletal muscle and adipocytes. Although the results presented here need to be validated in primary cells and in in vivo models, they provide a preliminary picture of the consequent effects of this inhibition on hepatic gluconeogenesis and, in part, the mechanisms involved. As TNFa is a major adipocytokine associated with obesity and type 2 diabetes, this pathway of impairment of insulin action, as observed in HepG2 cells mediated by Foxa2, possibly explains one of the contributory mechanisms for the observed hyperglycaemia in obese diabetics. Materials and methods Materials DMEM, antibiotic–antimycotic, protein A-Sepharose, human insulin and TNFa were purchased from Sigma (St. Louis, MO, USA). The glucose assay, protein estimation and RNeasy kits were obtained from Merck (Darmstadt, Germany), Biorad Laboratories (Hercules, CA, USA) and Qiagen (Hilden, Germany), respectively. SYBR Green Real Time PCR Master Mix was purchased from Applied Biosys- tems (Foster City, CA, USA). Foxa2, Foxo1, TATA box-binding protein (TBP) and b -actin primary antibodies were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA), whereas those of p-Akt and total Akt were purchased from Cell Signaling Technology (Danvers, MA, USA). All secondary antibodies used were obtained from Bangalore Genei, India. All other chemicals and reagents used were purchased from Sigma. Control and Foxa2 siRNA was obtained from Santa Cruz Biotechnology Inc. Cell culture All experiments were performed in HepG2 (human hepato- cellular carcinoma) cells obtained from the National Centre for Cell Science, Pune, India. HepG2 cells have been reported to confer many hepatocyte functions [27] and thereby to serve as a resource for metabolic studies [28]. These cells are extensively used for the study of insulin sig- nalling and hepatic glucose output [62–65]. Cells were main- tained in DMEM supplemented with 10% fetal calf serum and 1% antibiotic–antimycotic (100 unitsÆmL )1 penicillin, 0.1 mgÆmL )1 streptomycin and 0.25 lgÆmL )1 amphotericin B) at 37 °C in a humidified atmosphere of 5% CO 2 . All incubations were carried out after overnight serum starvation. Western blotting HepG2 cells were plated in six-well plates and incubated with TNFa (1 nm, 24 h) or insulin (50 nm, 15 min), or Effect of TNFa on insulin action on PEPCK expression A. K. Pandey et al. 3764 FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS preincubated with TNFa followed by insulin treatment. On termination of incubation, cells were lysed in ice-cold lysis buffer [10 mm Tris, 50 mm NaCl, 1% Triton X-100, 5 mm EDTA, 20 mm sodium pyrophosphate, 50 mm NaF, 100 lm Na 3 VO 4 ,5lgÆmL )1 each of leupeptin, aprotinin and pepstatin, and 1 m m phenylmethylsulphonyl fluoride (pH 7.4)]. Lysates were centrifuged at 10 000 g for 10 min at 4 °C, and the supernatant was used as the cytosolic prep- aration. To the pellet, 50 lLof10mm Tris (pH 7.5) con- taining 10% v ⁄ v glycerol, 0.1 m KCl, 0.2 mm EDTA, 20 mm sodium pyrophosphate, 50 mm NaF, 100 lm Na 3 VO 4 ,5lgÆmL )1 each of leupeptin, aprotinin and pepst- atin, and 1 mm phenylmethylsulphonyl fluoride was added and stirred at 4 °C for 30 min. These nuclear extracts were centrifuged at 15 000 g for 20 min at 4 ° C, and the super- natant was used as the nuclear fraction. Equal amounts of nuclear and cytosolic proteins were resolved by SDS-PAGE, transferred to poly(vinylidene difluoride) mem- branes and probed with p-Akt, Akt, Foxa2 and Foxo1 antibodies. Blots were probed identically for b-actin or TBP, and taken as the loading controls, and also to assess the purity of nuclear and cytosolic preparations. Bands were analysed densitometrically as described below. Immunofluoresence microscopy HepG2 cells were treated as described above with TNFa (1 nm) and ⁄ or insulin (50 nm), or in the absence of any of these (control). On termination of incubation, cells were fixed for 15 min at room temperature with 3.5% parafor- maldehyde. The cells were then permeabilized with 0.5% Triton X-100 and incubated with anti-Foxa2 IgG (1 : 50) for 2 h at room temperature. After washing, the cells were treated with anti-goat secondary IgG linked to fluorescein isothiocyanate (1 : 100) for 2 h at room temperature. The cells were then washed thoroughly, 4¢,6-diamidino-2-pheny- lindole (DAPI) was added to a final concentration of 1 lgÆmL )1 and the cells were visualized in a fluorescent microscope (Carl Zeiss Inc., New York, NY, USA). Chromatin immunoprecipitation assay Cells were treated with either TNFa (1 nm, 24 h) or insulin (50 nm, 15 min) alone, or pretreated with TNFa followed by insulin incubation. On termination of incubation, chro- matin was isolated according to the method of Buser et al. [66]. Twenty per cent of the chromatin preparation was reserved as the total input control and the remainder was incubated overnight at 4 °C in the presence of either nor- mal IgG or anti-Foxa2 IgG (5 lg). Immune complexes were reverse crosslinked and the Foxa2 enrichment of the target DNA fragments in the immunoprecipitated DNA was checked by PCR and quantified by real-time PCR. In both cases, the sequences of sense and antisense primers used were 5¢-GCCTGTGTGTCCTCAAAACC-3¢ and 5¢-GCAACTGTCCCTTGTCAAAA-3¢, respectively, which were specific to the Foxa2 binding site within the human PEPCK promoter. PCRs were performed in the presence of 0.25 mm dNTPs, 1.5 mm MgCl 2 , 10 pmol of each primer and 0.5 U Taq polymerase, and consisted of 35 cycles of denaturation at 94 °C for 45 s, annealing at 58 °C for 30 s and extension at 72 °C for 30 s (10 min last cycle; Gene- Amp PCR System 9700, Applied Biosystems). PCR prod- ucts were separated on a 1.0% agarose gel, photographed with the Alpha Innotech gel documentation system and the intensity of each band was analysed densitometrically and plotted after normalization to that of the input DNA. For real-time PCR, reaction components were put together using the SYBR Green PCR Master Mix (Applied Biosys- tems), and the reactions were performed according to the manufacturer’s instructions (ABI 7500, Applied Biosys- tems). Reactions were performed in triplicate and the rela- tive quantity was determined by the relative standard curve method. Values were normalized to those of input DNA and the control was arbitrarily assigned a value of unity. RNA isolation, RT-PCR and quantitative real-time PCR The subsequent effects of TNFa incubation prior to insulin treatment, or insulin or TNFa treatments alone, on the transcript levels of gluconeogenic genes were examined as described by Gabbay et al. [67]. Cells were incubated either in the presence of TNFa (1 nm) for 24 h, followed by insu- lin (50 nm) for 4 h, or with insulin or TNFa alone, or in the absence of any of these agents. Total RNA was extracted using the RNeasy kit (Qiagen), reverse tran- scribed and amplified (GeneAmp PCR System 9700, Applied Biosystems) with gene-specific primers (PEPCK: sense, 5¢-GGTTCCCAGGGTGCATGAAA-3¢; antisense, 5¢-CACGTAGGGTGAATCCGTCAG-3¢; G6Pase: sense, 5¢-ATGAGTCTGGTTACTACAGCCA-3¢; antisense, 5¢- AAGACAGGGCCGTCATTATGG-3¢). All reactions were performed in triplicate and expression levels were normal- ized to those of 18S rRNA. Real-time PCR for quantifica- tion was performed as described above, according to the manufacturer’s instructions (ABI 7500, Applied Biosys- tems). Reactions were performed in triplicate and the expression of each transcript was quantified by the relative standard curve method and normalized to that of 18S rRNA. The transcript value for the control obtained after normalization was arbitrarily assigned a value of unity. To further validate the role of Foxa2, HepG2 cells were trans- fected with 100 nm of either control or Foxa2 siRNA (Santa Cruz Biotechnology Inc.), according to the manufac- turer’s instructions. After allowing the cells to grow in fresh DMEM for 48 h, they were incubated with insulin or TNFa, or pretreated with TNFa prior to insulin, as men- tioned above. Cells incubated in the absence of any of these were taken as the control. On termination of incubation, A. K. Pandey et al. Effect of TNFa on insulin action on PEPCK expression FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS 3765 RNA was isolated and the status of PEPCK was deter- mined by real-time PCR, as described previously. Glucose production assay Glucose production was carried out essentially as described previously [63] with slight modifications. Briefly, after over- night serum starvation, HepG2 cells were incubated with TNFa (1 nm, 24 h) or insulin (50 nm, 24 h), or pretreated with TNFa prior to insulin incubation. Glucose released into the medium was assayed by subsequent incubation in glucose production medium [glucose- and phenol red-free DMEM containing the gluconeogenic substrates, sodium lactate (20 mm) and sodium pyruvate (2 mm)] and measure- ment of the glucose concentration using the glucose assay kit (Merckotest Glucose kit, Merck). This was normalized with total cellular protein measured using the protein assay kit (Biorad Laboratories). Densitometric analysis Each band, when mentioned, was analysed by alpha digi- doc 1201 software (Alpha Innotech Corporation, San Leandro, CA, USA). The same sized rectangular box was drawn surrounding each band and the intensity of each was analysed by the program after subtraction of the back- ground intensity. Statistical analysis All experiments were performed in triplicate and the data are presented as the mean ± standard error of the mean (SEM). Student’s t-test was used for statistical analysis and P < 0.05 was taken to be statistically significant. Acknowledgements This work was supported by an Indian National Sci- ence Academy (INSA) Young Scientist Project grant (INSA, New Delhi, India; SPYSP-51 ⁄ 2006 ⁄ 3705). A.K.P. acknowledges the receipt of a fellowship from the Council of Scientific and Industrial Research, New Delhi, India (NWP0036). The authors also thank Dr S. Chandna (Institute of Nuclear Medicine and Allied Sciences, DRDO, India) for the fluorescent microscopic images. References 1 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS & Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. J Am Med Assoc 289, 76–79. 2 Zimmet P, Alberti KG & Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414, 782–787. 3 Pittas AG, Joseph NA & Greenberg AS (2004) Adipo- cytokines and insulin resistance. J Clin Endocrinol Metab 89, 447–452. 4 Hotamisligil GS, Murray DL, Choy LN & Spiegelman BM (1994) Tumor necrosis factor alpha inhibits signal- ing from the insulin receptor. Proc Natl Acad Sci USA 91, 4854–4858. 5 Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH & Bryer-Ash M (1998) An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF- alpha)-induced insulin resistance: evidence for differen- tial regulation of insulin signaling by TNF-alpha. Endocrinology 139, 4928–4935. 6 Liu LS, Spelleken M, Rohrig K, Hauner H & Eckel J (1998) Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor. Diabetes 47, 515–522. 7 Boden G & Shulman GI (2002) Free fatty acids in obes- ity and type 2 diabetes: defining their role in the devel- opment of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32(Suppl 3), 14–23. 8 Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Goto H, Nakatani K et al. (1998) Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocri- nol Metab 83, 859–862. 9 Hotamisligil GS, Shargill NS & Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87–91. 10 Hamann A, Benecke H, Le Marchand-Brustel Y, Susu- lic VS, Lowell BB & Flier JS (1995) Characterization of insulin resistance and NIDDM in transgenic mice with reduced brown fat. Diabetes 44, 1266–1273. 11 Hotamisligil GS, Arner P, Caro JF, Atkinson RL & Spiegelman BM (1995) Increased adipose tissue expres- sion of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95, 2409–2415. 12 Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R & Simsolo RB (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95, 2111–2119. 13 Granner D, Andreone T, Sasaki K & Beale E (1983) Inhibition of transcription of the phosphoenolpyruvate carboxykinase gene by insulin. Nature 305, 549–551. 14 Spiegelman BM & Heinrich R (2004) Biological control through regulated transcriptional coactivators. Cell 119, 157–167. Effect of TNFa on insulin action on PEPCK expression A. K. Pandey et al. 3766 FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS [...]... lipoprotein, cholesterol, and bile acids FASEB J 4, 161–168 29 Gupta D, Varma S & Khandelwal RL (2007) Longterm effects of tumor necrosis factor-alpha treatment on insulin signaling pathway in HepG2 cells and HepG2 cells overexpressing constitutively active Akt ⁄ PKB J Cell Biochem 100, 593–607 30 Gupta D & Khandelwal RL (2004) Modulation of insulin effects on phosphorylation of protein kinase B and glycogen... (2007) Progesterone receptor repression of prolactin ⁄ signal transducer and activator of transcription 5-mediated transcription of the beta-casein gene in mammary epithelial cells Mol Endocrinol 21, 106–125 67 Gabbay A, Sutherland C, Gnudi L, Kahn BB, O’Brien RM, Granner DK & Flier JS (1996) Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras ⁄... sensitivity and protein tyrosine phosphatase 1B expression Mol Endocrinol 18, 1333–1345 65 Senn JJ, Klover PJ, Nowak IA & Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes Diabetes 51, 3391–3399 Effect of TNFa on insulin action on PEPCK expression 66 Buser AC, Gass-Handel EK, Wyszomierski SL, Doppler W, Leonhardt SA, Schaack J, Rosen JM, Watkin H, Anderson SM & Edwards... DK (2007) Insulin represses phosphoenolpyruvate carboxykinase gene transcription by causing the rapid disruption of an active transcription complex: a potential epigenetic effect Mol Endocrinol 21, 550–563 52 Hill MR & McCallum RE (1992) Identification of tumor necrosis factor a as a transcriptional regulator of phosphoenolpyruvate carboxykinase gene following endotoxin treatment in mice Infect Immun... H4IIE-hepatoma cells Biochem Biophys Res Commun 285, 897–902 Effect of TNFa on insulin action on PEPCK expression 27 Mavri-Damelin D, Eaton S, Damelin LH, Rees M, Hodgson HJ & Selden C (2007) Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2 Int J Biochem Cell Biol 39, 555–564 28 Javitt BN (1990) HepG2 cells as... (1995) Loss of hepatic autoregulation after carbohydrate overfeeding in normal man J Clin Invest 96, 1967–1972 FEBS Journal 276 (2009) 3757–3769 ª 2009 The Authors Journal compilation ª 2009 FEBS 3767 Effect of TNFa on insulin action on PEPCK expression A K Pandey et al 40 Niswender KD, Shiota M, Postic C, Cherrington AD & Magnuson MA (1997) Effects of increased glucokinase gene copy number on glucose... (2006) Adipose overexpression of phosphoenolpyruvate carboxykinase leads to high susceptibility to dietinduced insulin resistance and obesity Diabetes 55, 273–280 58 Ling PR, Bistrian BR, Mendez B & Istfan NW (1994) Effects of systemic infusions of endotoxin, tumor necrosis factor, and interleukin-1 on glucose metabolism in the rat: relationship to endogenous glucose production and peripheral tissue... D (2001) The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression J Clin Invest 108, 1359–1367 26 Barthel A, Schmoll D, Kruger KD, Bahrenberg G, Walther R, Roth RA & Joost HG (2001) Differential regulation of endogenous glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression by the forkhead transcription factor FKHR in H4IIE-hepatoma... Schutz G (1999) Inactivation of the winged helix transcription factor HNF3alpha affects glucose homeostasis and islet glucagon gene expression in vivo Genes Dev 13, 495–504 45 Rausa FM, Tan Y, Zhou H, Yoo KW, Stolz DB, Watkins SC, Franks RR, Unterman TG & Costa RH (2000) Elevated levels of hepatocyte nuclear factor 3bS in mouse hepatocytes in uence expression of genes involved in bile acid and glucose... Pandey et al 15 Saltiel AR & Kahn CR (2001) Insulin signaling and the regulation of glucose and lipid metabolism Nature 414, 799–806 16 Kaestner KH, Hiemisch H, Luckow B & Schutz G (1994) The HNF-3 gene family of transcription factors in mice: gene structure, cDNA sequence, and mRNA distribution Genomics 20, 377–385 17 Wolfrum C, Besser D, Luca E & Stoffel M (2003) Insulin regulates the activity of . Tumour necrosis factor-a attenuates insulin action on phosphoenolpyruvate carboxykinase gene expression and gluconeogenesis by altering the cellular localization. attenuated insulin- induced inhibition of the expression of gluconeogenic enzymes and hepatic glucose production. Insulin inhibition of PEPCK expression and the